Cover Image
市場調查報告書

NewLink Genetics Corporation:產品平台分析

NewLink Genetics Corporation - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224685
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
NewLink Genetics Corporation:產品平台分析 NewLink Genetics Corporation - Product Pipeline Review - 2016
出版日期: 2016年04月27日 內容資訊: 英文 53 Pages
簡介

NewLink Genetics Corporation 是開發治療各種癌症用免疫療法產品之生物製藥公司。

本報告提供NewLink Genetics Corporation的治療藥開發平台現況及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

NewLink Genetics Corporation的基本資料

  • NewLink Genetics Corporation概要
  • 主要資訊
  • 企業資料

NewLink Genetics Corporation:R&D概要

  • 主要的治療範圍

NewLink Genetics Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

NewLink Genetics Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

NewLink Genetics Corporation:藥物簡介

  • algenpantucel-L
  • tergenpumatucel-L
  • dorgenmeltucel-L
  • indoximod
  • 前列腺癌HyperAcute
  • 腎臟癌HyperAcute
  • 流感疫苗
  • 癌症治療用阻礙IDO及TDO的小分子
  • 癌症治療用阻礙IDO的途徑的小分子
  • 癌症治療用阻礙TDO的小分子
  • 黃熱病/arenavirus vaccine

NewLink Genetics Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

NewLink Genetics Corporation:最近的開發平台趨勢

NewLink Genetics Corporation:暫停中的計劃

NewLink Genetics Corporation:企業發表

NewLink Genetics Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08037CDB

Summary

Global Markets Direct's, 'NewLink Genetics Corporation - Product Pipeline Review - 2016', provides an overview of the NewLink Genetics Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by NewLink Genetics Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of NewLink Genetics Corporation
  • The report provides overview of NewLink Genetics Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses NewLink Genetics Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features NewLink Genetics Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate NewLink Genetics Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for NewLink Genetics Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding NewLink Genetics Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • NewLink Genetics Corporation Snapshot
    • NewLink Genetics Corporation Overview
    • Key Information
    • Key Facts
  • NewLink Genetics Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • NewLink Genetics Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • NewLink Genetics Corporation - Pipeline Products Glance
    • NewLink Genetics Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • NewLink Genetics Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • NewLink Genetics Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • NewLink Genetics Corporation - Drug Profiles
    • algenpantucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • indoximod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tergenpumatucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dorgenmeltucel-L
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Hormone Refractory Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H5N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain A/H7N9] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [strain H1N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit IDO and TDO for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit TDO for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (arenavirus + yellow fever) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Zika virus vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • NewLink Genetics Corporation - Pipeline Analysis
    • NewLink Genetics Corporation - Pipeline Products by Target
    • NewLink Genetics Corporation - Pipeline Products by Route of Administration
    • NewLink Genetics Corporation - Pipeline Products by Molecule Type
    • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action
  • NewLink Genetics Corporation - Recent Pipeline Updates
  • NewLink Genetics Corporation - Dormant Projects
  • NewLink Genetics Corporation - Company Statement
  • NewLink Genetics Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • NewLink Genetics Corporation, Key Information
  • NewLink Genetics Corporation, Key Facts
  • NewLink Genetics Corporation - Pipeline by Indication, 2016
  • NewLink Genetics Corporation - Pipeline by Stage of Development, 2016
  • NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016
  • NewLink Genetics Corporation - Combination Treatment Modalities in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • NewLink Genetics Corporation - Phase III, 2016
  • NewLink Genetics Corporation - Phase II, 2016
  • NewLink Genetics Corporation - Phase I, 2016
  • NewLink Genetics Corporation - Preclinical, 2016
  • NewLink Genetics Corporation - Discovery, 2016
  • NewLink Genetics Corporation - Pipeline by Target, 2016
  • NewLink Genetics Corporation - Pipeline by Route of Administration, 2016
  • NewLink Genetics Corporation - Pipeline by Molecule Type, 2016
  • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016
  • NewLink Genetics Corporation - Recent Pipeline Updates, 2016
  • NewLink Genetics Corporation - Dormant Developmental Projects,2016
  • NewLink Genetics Corporation, Other Locations
  • NewLink Genetics Corporation, Subsidiaries

List of Figures

  • NewLink Genetics Corporation - Pipeline by Top 10 Indication, 2016
  • NewLink Genetics Corporation - Pipeline by Stage of Development, 2016
  • NewLink Genetics Corporation - Monotherapy Products in Pipeline, 2016
  • NewLink Genetics Corporation - Out-Licensed Products in Pipeline, 2016
  • NewLink Genetics Corporation - Pipeline by Target, 2016
  • NewLink Genetics Corporation - Pipeline by Route of Administration, 2016
  • NewLink Genetics Corporation - Pipeline by Molecule Type, 2016
  • NewLink Genetics Corporation - Pipeline Products by Mechanism of Action, 2016
Back to Top